Cargando…

Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers

HEALTH ISSUE: In Canada, cancers of the endometrium, ovaries, vulva, vagina, placenta and adnexa account for 11% of all malignant neoplasms in women and 81% of all genital cancers. Although the incidence and mortality from vulvar and vaginal cancers are very low, endometrium and ovarian cancer are i...

Descripción completa

Detalles Bibliográficos
Autores principales: Duarte-Franco, Eliane, Franco, Eduardo L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2096678/
https://www.ncbi.nlm.nih.gov/pubmed/15345077
http://dx.doi.org/10.1186/1472-6874-4-S1-S14
_version_ 1782138255931604992
author Duarte-Franco, Eliane
Franco, Eduardo L
author_facet Duarte-Franco, Eliane
Franco, Eduardo L
author_sort Duarte-Franco, Eliane
collection PubMed
description HEALTH ISSUE: In Canada, cancers of the endometrium, ovaries, vulva, vagina, placenta and adnexa account for 11% of all malignant neoplasms in women and 81% of all genital cancers. Although the incidence and mortality from vulvar and vaginal cancers are very low, endometrium and ovarian cancer are important public health problems. KEY FINDINGS: In Canada, there has been no appreciable improvement in survival for women with advanced endometrial (EC) or ovarian cancer (OC) over the past 30 years. The prognosis of EC is good for most patients because diagnosis is made at early stages. However, survival of OC is poor; more than 70% of cases are diagnosed at late stages. Up to 10% of OCs is linked to familial aggregation. Cancers of the vulva and of the vagina are very rare. The survival experience for women with the latter is worse than for those with the former. Both share many risk factors with cervical cancer and the recent developments in the study of HPV infection should be applicable to these diseases as well. Of particular interest will be the advent of vaccines for the primary prevention of HPV infection. DATA GAPS AND RECOMMENDATIONS: At present, the best available means to diagnose gynecologic malignancies is a detailed clinical examination, considering the totality of information on potential and proven risk factors, such as age, reproductive health, sexual practices, use unopposed estrogens or of oral contraceptives or tubal ligation, obesity, diet, smoking, and the familial clustering of some of these cancers.
format Text
id pubmed-2096678
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-20966782007-11-29 Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers Duarte-Franco, Eliane Franco, Eduardo L BMC Womens Health Report HEALTH ISSUE: In Canada, cancers of the endometrium, ovaries, vulva, vagina, placenta and adnexa account for 11% of all malignant neoplasms in women and 81% of all genital cancers. Although the incidence and mortality from vulvar and vaginal cancers are very low, endometrium and ovarian cancer are important public health problems. KEY FINDINGS: In Canada, there has been no appreciable improvement in survival for women with advanced endometrial (EC) or ovarian cancer (OC) over the past 30 years. The prognosis of EC is good for most patients because diagnosis is made at early stages. However, survival of OC is poor; more than 70% of cases are diagnosed at late stages. Up to 10% of OCs is linked to familial aggregation. Cancers of the vulva and of the vagina are very rare. The survival experience for women with the latter is worse than for those with the former. Both share many risk factors with cervical cancer and the recent developments in the study of HPV infection should be applicable to these diseases as well. Of particular interest will be the advent of vaccines for the primary prevention of HPV infection. DATA GAPS AND RECOMMENDATIONS: At present, the best available means to diagnose gynecologic malignancies is a detailed clinical examination, considering the totality of information on potential and proven risk factors, such as age, reproductive health, sexual practices, use unopposed estrogens or of oral contraceptives or tubal ligation, obesity, diet, smoking, and the familial clustering of some of these cancers. BioMed Central 2004-08-25 /pmc/articles/PMC2096678/ /pubmed/15345077 http://dx.doi.org/10.1186/1472-6874-4-S1-S14 Text en Copyright © 2004 Duarte-Franco and Franco; licensee BioMed Central Ltd http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Report
Duarte-Franco, Eliane
Franco, Eduardo L
Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers
title Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers
title_full Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers
title_fullStr Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers
title_full_unstemmed Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers
title_short Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers
title_sort other gynecologic cancers: endometrial, ovarian, vulvar and vaginal cancers
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2096678/
https://www.ncbi.nlm.nih.gov/pubmed/15345077
http://dx.doi.org/10.1186/1472-6874-4-S1-S14
work_keys_str_mv AT duartefrancoeliane othergynecologiccancersendometrialovarianvulvarandvaginalcancers
AT francoeduardol othergynecologiccancersendometrialovarianvulvarandvaginalcancers